Salbutamol Dragon Pharma: Compound Profile
Salbutamol Dragon Pharma is a beta-2 adrenergic agonist compound belonging to the bronchodilator class of research chemicals. This selective sympathomimetic agent demonstrates high affinity for beta-2 adrenergic receptors and serves as a valuable tool for investigating cellular signalling pathways in laboratory settings. Researchers at Stroid UK Shop utilise this compound to study bronchodilator mechanisms, cellular energy metabolism, and sympathetic nervous system modulation in controlled experimental environments.
Laboratory Applications
Scientific investigations examine salbutamol’s interaction with beta-2 adrenergic receptors and downstream cellular cascades including cyclic adenosine monophosphate (cAMP) elevation and protein kinase A activation. Research applications focus on bronchial smooth muscle relaxation mechanisms, metabolic rate modulation, and cellular energy expenditure pathways. Studies investigate the compound’s selectivity profile compared to other adrenergic agonists available through specialised research chemical suppliers. Laboratory protocols examine receptor binding kinetics, tissue selectivity, and pharmacological activity in various cellular models alongside other research compounds like those found in SARM collections and peptide research libraries.
Technical Specifications
| Parameter | Specification |
|---|---|
| Chemical Name | Salbutamol |
| CAS Number | 18559-94-9 |
| Molecular Formula | C₁₃H₂₁NO₃ |
| Molecular Weight | 239.31 g/mol |
| Mechanism | Beta-2 adrenergic receptor agonist |
| Storage | Room temperature, dry environment |
| Manufacturer | Dragon Pharma |
| Research Use | Laboratory investigations only |
Research Compliance
This salbutamol preparation from Dragon Pharma is manufactured exclusively for in-vitro laboratory research applications. The compound is not intended for human consumption, therapeutic use, or any application outside controlled scientific environments. Researchers must ensure proper laboratory protocols, safety procedures, and regulatory compliance when conducting investigations with this beta-2 adrenergic agonist. All studies should be performed by qualified personnel in appropriately equipped research facilities with adequate ventilation and safety measures.
